Skip to main content

Advertisement

SpringerLink
Log in

Management of Depression After Myocardial Infarction

  • Psychological Aspects of Cardiovascular Diseases (A Steptoe, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Depression in patients who have had a myocardial infarction is an important clinical problem because it is extremely common and because the comorbidity complicates depression treatment and worsens the cardiovascular prognosis. Studies of psychotherapy, exercise, pharmacotherapy, and collaborative care demonstrate that effective treatment of depression is possible but the strength of the effects seen in most studies is low, and cardiovascular and all-cause morbidity and mortality benefits have not been proven. Recent collaborative care studies have had promising outcomes. For pharmacotherapy, side effects, including bleeding and arrhythmia risks, require special attention. Recovery from depression is associated with better long-term cardiovascular prognosis, while treatment per se is not.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322. This annual update from the American Heart Association provides a wealth of useful material.

    Article  PubMed  Google Scholar 

  2. Centers for Disease Control and Prevention. Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors—United States, 2011. MMWR. 2011;60:1248–51.

    Google Scholar 

  3. España-Romero V, Artero EG, Lee D-C, Sui X, Baruth M, Ruiz JR, et al. A prospective study of ideal cardiovascular health and depressive symptoms. Psychosomatics. 2013;54:525–35.

    Article  PubMed  Google Scholar 

  4. Doyle F, Rohde D, Rutkowska A, Morgan K, Cousins G, McGee H. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990 to 2013. Psychosom Med. 2015;76:44–57.

    Article  Google Scholar 

  5. Riegel B, Lee CS, Dickson VV. Self-care in patients with chronic heart failure. Nat Rev Cardiol. 2011;8:644–54.

    Article  PubMed  Google Scholar 

  6. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802–13.

    Article  PubMed  Google Scholar 

  7. van Melle JP, de Jonge P, Spijkerman TA, Tijssen JGP, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66:814–22.

    Article  PubMed  Google Scholar 

  8. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of acute myocardial infarction. Review of the evidence. J Gen Intern Med. 2006;21:30–8.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Doyle F, McGee H, Conroy R, Conradi HJ, Meijer A, Steeds R, et al. Systematic review and individual patient data meta-analysis of sex differences in depression and prognosis in persons with myocardial infarction: a MINDMAPS study. Psychosom Med. 2015;77:419–28.

    Article  PubMed  Google Scholar 

  10. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27:2763–74.

    Article  PubMed  Google Scholar 

  11. Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry. 2013;203(2):90–102. doi:10.1192/bjp.bp.112.111195.

    Article  CAS  PubMed  Google Scholar 

  12. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129:1350–69. This is an authoritative review of depression as a risk factor for recurrent cardiovascular events and mortality in patients with acute coronary events.

    Article  PubMed  Google Scholar 

  13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington VA: American Psychiatric Association; 2013.

    Google Scholar 

  14. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.

    Article  CAS  PubMed  Google Scholar 

  15. Lichtman JH, Bigger Jr JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, et al. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. A science advisory from the American Heart Association prevention committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2008;118:1768–75.

    Article  PubMed  Google Scholar 

  16. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–92.

    Article  PubMed  Google Scholar 

  17. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Patient Health Questionnaire screeners. [last accessed 29 May 2015]; Available from: http://www.phqscreeners.com/overview.aspx.

  19. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JTJ, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–9.

    Article  CAS  PubMed  Google Scholar 

  20. Glassman AH, Bigger JTJ, Gaffney M, Shapiro PA, Swenson JR. Onset of major depression associated with acute coronary syndromes. Relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry. 2006;63:283–8.

    Article  PubMed  Google Scholar 

  21. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170:600–8. This is the first study demonstrating the value of implementation of the collaborative care IMPACT model in post-MI patients.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Writing Committee for the ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA. 2003;289:3106–16.

    Article  Google Scholar 

  23. Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) Study. Psychosom Med. 2004;66:466–74.

    Article  PubMed  Google Scholar 

  24. Unutzer J, Katon W, Callahan CM, Williams Jr JW, Hunkeler E, Harpole L, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836–45.

    Article  PubMed  Google Scholar 

  25. Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES. Interpersonal psychotherapy of depression. New York: Basic Books; 1984.

    Google Scholar 

  26. Lesperance F, Frasure-Smith N, Koszycki D, Laliberte M-A, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367–79.

    Article  CAS  PubMed  Google Scholar 

  27. Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol. 2009;169(9):1158–65.

    Article  PubMed  Google Scholar 

  28. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, West R, Moxham T, Thompson David R, Taylor Rod S. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev [serial on the Internet]. 2011;(8):CD002902. doi:10.1002/14651858.CD002902.pub3.

  29. Dickens C, Cherrington A, Adeyemi I, Roughley K, Bower P, Garrett C, et al. Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med. 2013;75:211–21.

    Article  PubMed  Google Scholar 

  30. Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med. 2013;75:335–49.

    Article  PubMed  Google Scholar 

  31. Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results From the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol. 2012;60:1053–63. This study dramatically illustrates the value of sustained aerobic exercise therapy for depression in patients with coronary disease.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Blumenthal J, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-Action randomized trial. JAMA. 2012;308:465–74. This study demonstrates both a survival benefit and a depression benefit of exercise for depressed patients with CHF.

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Strik JJMH, Honig A, Lousberg R, Lousberg AHP, Cheriex EC, Tuynman-Qua HG, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783–9.

    Article  CAS  PubMed  Google Scholar 

  34. Glassman AH, Bigger Jr JT, Gaffney M. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. Arch Gen Psychiatry. 2009;66:1022–9.

    Article  PubMed  Google Scholar 

  35. McFarlane A, Kamath MV, Fallen EL, Malcolm V, Cherian F, Norman G. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J. 2001;142:617–23.

    Article  CAS  PubMed  Google Scholar 

  36. Mohapatra P, Kar N, Kar G, Behera M. Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: six month prospective study on outcome. Clin Pract Epidemiol Ment Health. 2005;1:26.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Michalakeas CA, Parissis JT, Douzenis A, Nikolaou M, Varounis C, Andreadou I, et al. Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. J Card Fail. 2011;17:748–54.

    Article  CAS  PubMed  Google Scholar 

  38. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56:692–9.

    Article  PubMed Central  PubMed  Google Scholar 

  39. van Zyl LT, Lesperance F, Frasure-Smith N, Malinin AI, Atar D, Laliberte MA, et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J Thromb Thrombolysis. 2009;27:48–56.

    Article  CAS  PubMed  Google Scholar 

  40. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. This study provides a useful picture of the correlation of antidepressant dose with QT interval for many antidepressants and illustrates that citalopram has the steepest dose–response relationship.

    Article  PubMed Central  PubMed  Google Scholar 

  41. FDA Drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. www.fda.gov/Drugs/%20DrugSafety/ucm297391.htm (last accessed 29 May 2015)

  42. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, et al. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther. 2012;92:72–9.

    Article  CAS  PubMed  Google Scholar 

  43. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics. 2015;56:36–43.

    Article  PubMed  Google Scholar 

  44. Zivin K, Pfeiffer PN, Bohnert ASB, Ganoczy D, Blow FC, Nallamothu BK, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatr. 2013;170:642–50.

    Article  PubMed  Google Scholar 

  45. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf. 2011;20:903–13.

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Scherrer JF, Garfield LD, Lustman PJ, Hauptman PJ, Chrusciel T, Zeringue A, et al. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med. 2011;124:318–24.

    Article  PubMed  Google Scholar 

  47. Kim JM, Bae KY, Stewart R, Jung BO, Kang HJ, Kim SW, et al. Escitalopram treatment for major depressive disorder following acute coronary syndrome: a 24-week double-blind placebo-controlled trial. J Clin Psychiatry. 2015;76(1):62–8. This is the newest published randomized double blind placebo controlled trial of an antidepressant for treatment of depression after an acute coronary event.

    Article  PubMed  Google Scholar 

  48. Gottlieb SS, Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153:868–73.

    Article  CAS  PubMed  Google Scholar 

  49. Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, et al. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med. 2015;7:277ra31. This preclinical study highlights the potentially beneficial pleiotropic effects of paroxetine on cardiac function.

    Article  CAS  PubMed  Google Scholar 

  50. Kim DH, Daskalakis C, Whellan DJ, Whitman IR, Hohmann S, Medvedev S, et al. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol. 2009;103:1391–5.

    Article  CAS  PubMed  Google Scholar 

  51. Xiong GL, Jiang W, Clare RM, Shaw LK, Smith PK, O’Connor CM, et al. Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. Clin Cardiol. 2010;33:E94–8.

    Article  PubMed  Google Scholar 

  52. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183:1835–43.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Schelleman H, Brensinger CM, Bilker WB, Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case–control study. PLoS ONE. 2011;6, e21447. doi:10.1371/journal.pone.0021447.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33:433–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Wallerstedt SM, Gleerup H, Sundstrom A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients–influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;18:412–6.

    Article  CAS  PubMed  Google Scholar 

  56. van Melle JP, de Jonge P, Honig A, Schene AH, Kuyper AMG, Crijns HJGM, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460–6.

    Article  PubMed  Google Scholar 

  57. Honig A, Kuyper AMG, Schene AH, van Melle JP, de Jonge P, Tulner DM, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69:606–13.

    Article  CAS  PubMed  Google Scholar 

  58. de Jonge P, Honig A, van Melle JP, Schene AH, Kuyper AMG, Tulner D, et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry. 2007;164:1371–8.

    Article  PubMed  Google Scholar 

  59. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991;148:512–6.

    Article  CAS  PubMed  Google Scholar 

  60. Lesperance F, Frasure-Smith N, Laliberte MA, White M, Lafontaine S, Calderone A, et al. An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Can J Psychiatry. 2003;48:695–701.

    PubMed  Google Scholar 

  61. Glassman AH, Roose SP, Bigger Jr JT. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA. 1993;269:2673–5.

    Article  CAS  PubMed  Google Scholar 

  62. Peyre H, Hoertel N, Hatteea H, Limosin F, Dubuc C, Delorme R. Adulthood self-reported cardiovascular risk and ADHD medications: results from the 2004–2005 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2014;75:181–2.

    Article  PubMed  Google Scholar 

  63. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–904.

    Article  CAS  PubMed  Google Scholar 

  64. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127:1102–10.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792–8.

    Article  CAS  PubMed  Google Scholar 

  66. Zuidersma M, Conradi HJ, van Melle JP, Ormel J, de Jonge P. Depression treatment after myocardial infarction and long-tem risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res. 2013;74:25–30.

    Article  PubMed  Google Scholar 

  67. Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M, et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33:745–51.

    Article  CAS  PubMed  Google Scholar 

  68. Rieckmann N, Kronish IM, Shapiro PA, Whang W, Davidson KW. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study. JAMA Intern Med. 2013;173:1150–1.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Krivoy A, Balicer RD, Feldman B, Hoshen M, Zalsman G, Weizman A, et al. Adherence to antidepressant therapy and mortality rates in ischaemic heart disease: cohort study. Br J Psychiatry. 2015;206:297–301.

    Article  PubMed  Google Scholar 

  70. Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107:972–9.

    Article  CAS  PubMed  Google Scholar 

  71. Chung ML, Dekker RL, Lennie TA, Moser DK. Antidepressants do not improve event-free survival in patients with heart failure when depressive symptoms remain. Heart Lung. 2013;42:85–91.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Tousoulis D, Antoniades C, Drolias A, Stefanadi E, Marinou K, Vasiliadou C, et al. Selective serotonin reuptake inhibitors modify the effect of β-blockers on long-term survival of patients with end-stage heart failure and major depression. J Card Fail. 2008;14:456–64.

    Article  CAS  PubMed  Google Scholar 

  73. Diez-Quevedo C, Lupón J, González B, Urrutia A, Cano L, Cabanes R, et al. Depression, antidepressants, and long-term mortality in heart failure. Int J Cardiol. 2013;167:1217–25.

    Article  PubMed  Google Scholar 

  74. Katon WJ, Von Korff M, Lin EHB, Simon G, Ludman E, Russo J, et al. The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042–9.

    Article  PubMed  Google Scholar 

  75. Katon WJ, Lin EHB, Von Korff M, Ciechanowski P, Ludman EJ, Young B, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363:2611–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Stewart J, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Psychosom Med. 2014;76:29–37.

    Article  PubMed Central  PubMed  Google Scholar 

  77. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ, et al. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. JAMA. 2009;302:2095–103.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Davidson KW, Bigger JT, Burg MM, Carney RM, Chaplin WF, Czajkowski S, et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Intern Med. 2013;173:997–1004. This study extends the evidence for the effect of collaborative care of depression in post-ACS patients.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisle VC, Arthurs E, et al. Does Evidence Support the American Heart Association’s recommendation to screen patients for depression in cardiovascular care? An updated systematic review. PLoS ONE. 2013;8:e52654. This is a useful cautionary analysis of the limitations of the current state of screening, referral and treatment for depression in coronary disease patients.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med. 2014;174:927–35.

    Article  CAS  PubMed  Google Scholar 

  81. Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry. 2012;200:137–42.

    Article  PubMed  Google Scholar 

  82. Carney RM, Freedland KF. Is there a high-risk subtype of depression in patients with coronary heart disease? Curr Psychiatry Rep. 2012;14:1–7.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Shapiro PA. Depression treatment and coronary artery disease outcomes: time for reflection. J Psychosom Res. 2013;74:4–5.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Peter A. Shapiro declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article is a review of previously published studies supplemented with comments based on the author’s clinical experience. It does cite studies authored or co-authored by the author. However, this article is not a report of, and does not contain any primary report of, studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Columbia University Medical Center, 622 W. 168 St., Box 427, New York, NY, 10032, USA

    Peter A. Shapiro

Authors
  1. Peter A. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter A. Shapiro.

Additional information

This article is part of the Topical Collection on Psychological Aspects of Cardiovascular Diseases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shapiro, P.A. Management of Depression After Myocardial Infarction. Curr Cardiol Rep 17, 80 (2015). https://doi.org/10.1007/s11886-015-0634-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-015-0634-4

Keywords

Search

Navigation